Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Famitinib in Advanced Pulmonary Sarcomatoid Carcinoma
NCT04888429Phase 2Completed
- Start
- Jul 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, famitinib in pulmonary sarcomatoid carcinoma (PSC). Started Jul 2021; status: completed.
02
Drugs
camrelizumabfamitinib
03
Conditions
pulmonary sarcomatoid carcinoma (PSC)
Beyond the preview
Go deeper on NCT04888429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04888429.